Alphabet’s life sciences company Verily has signed an agreement to form a new US-based joint venture (JV) with health devices maker ResMed to help patients with sleep apnoea.
The JV will integrate ResMed’s sleep apnoea expertise and Verily’s health data analytics technologies to investigate the impacts of undiagnosed and untreated form of this condition on health and financial aspects.
In addition, the JV will work on development of software solutions to aid healthcare providers in efficient identification, diagnosis, treatment and management of people suffering from breathing-related sleep disorders, including sleep apnoea.
ResMed chief medical officer Carlos Nunez said: “The vast majority of people with sleep apnoea don’t realise they have it, and therefore don’t seek accessible, effective treatment to mitigate its effects and long-term health risks.
“The combined industry expertise, scalable infrastructure, and data analytics capabilities of ResMed and Verily can unlock meaningful ways to identify these individuals and support their journey to improved sleep, health and quality of life.”
Subject to customary closing conditions and regulatory approvals, the JV will operate as a stand-alone entity from the companies.
Verily chief medical and scientific officer Jessica Mega said: “Approaching a widespread health problem like sleep apnoea through collecting, organising and activating health data is central to Verily’s mission.
“By better identifying at-risk individuals as well as generating real-world evidence regarding the value and effectiveness of treatment, this collaboration has the potential to improve outcomes for millions of people living with sleep apnoea, and potentially other related conditions.”
Sleep apnoea is estimated to affect 54 million people in the US and can lead to heart disease, stroke, type 2 diabetes and other life-threatening conditions. Research showed the condition to be undiagnosed and untreated in 80% of the patients.